Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria

Chloroquine or dihydroartemisinin-piperaquine with either 7- or 14-day primaquine regimens provided highly effective radical cure of vivax malaria on the Thailand-Myanmar border. Short course higher dose primaquine regimens for vivax malaria radical cure may improve efficacy by improving adherence.

Download Full-text

Faculty Opinions recommendation of Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736238671.793565648 ◽

2019 ◽

Author(s):

Brian Eley

Keyword(s):

Plasmodium Vivax ◽

Vivax Malaria ◽

Radical Cure ◽

Short Course ◽

Plasmodium Vivax Malaria

Download Full-text

Faculty Opinions recommendation of Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736238671.793563192 ◽

2019 ◽

Author(s):

Gavin Koh

Keyword(s):

Plasmodium Vivax ◽

Vivax Malaria ◽

Radical Cure ◽

Short Course ◽

Plasmodium Vivax Malaria

Download Full-text

A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand

American Journal of Tropical Medicine and Hygiene ◽

10.4269/ajtmh.2010.09-0428 ◽

2010 ◽

Vol 82 (4) ◽

pp. 542-547 ◽

Cited By ~ 23

Author(s):

Sasithon Pukrittayakamee ◽

Nicholas J. White ◽

Kesinee Chotivanich ◽

Nicholas P. J. Day ◽

Mallika Imwong ◽

...

Keyword(s):

Plasmodium Vivax ◽

Vivax Malaria ◽

Radical Cure ◽

Short Course ◽

Plasmodium Vivax Malaria

Download Full-text

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(19)31285-1 ◽

2019 ◽

Vol 394 (10202) ◽

pp. 929-938 ◽

Cited By ~ 22

Author(s):

Walter R J Taylor ◽

Kamala Thriemer ◽

Lorenz von Seidlein ◽

Prayoon Yuentrakul ◽

Thanawat Assawariyathipat ◽

...

Keyword(s):

Plasmodium Vivax ◽

Vivax Malaria ◽

Radical Cure ◽

Short Course ◽

Plasmodium Vivax Malaria

Download Full-text

Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria

eLife ◽

10.7554/elife.62448 ◽

2021 ◽

Vol 10 ◽

Author(s):

Ghulam R Awab ◽

Fahima Aaram ◽

Natsuda Jamornthanyawat ◽

Kanokon Suwannasin ◽

Watcharee Pagornrat ◽

...

Keyword(s):

Protective Effect ◽

Plasmodium Vivax ◽

G6pd Deficiency ◽

Vivax Malaria ◽

Malaria Incidence ◽

Large Population ◽

Credible Interval ◽

Radical Cure ◽

Plasmodium Vivax Malaria ◽

Glucose 6 Phosphate Dehydrogenase

X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy. The severe Mediterranean variant (G6PD Med) found across Europe and Asia is thought to confer protection against malaria, but its effect is unclear. We fitted a Bayesian statistical model to observed G6PD Med allele frequencies in 999 Pashtun patients presenting with acute Plasmodium vivax malaria and 1408 population controls. G6PD Med was associated with reductions in symptomatic P. vivax malaria incidence of 76% (95% credible interval [CI], 58–88) in hemizygous males and homozygous females combined and 55% (95% CI, 38–68) in heterozygous females. Unless there is very large population stratification within the Pashtun (confounding these results), the G6PD Med genotype confers a very large and gene-dose proportional protective effect against acute vivax malaria. The proportion of patients with vivax malaria at risk of haemolysis following 8-aminoquinoline radical cure is substantially overestimated by studies measuring G6PD deficiency prevalence in healthy subjects.

Download Full-text